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Abstract
Background: The hydroxylated derivatives of cholesterol, such as the oxysterols, play important roles in lipid metabolism. In
particular, 25-hydroxycholesterol (25HC) has been implicated in a variety of metabolic events including cholesterol
homeostasis and atherosclerosis. 25HC is detectable in human plasma after ingestion of a meal rich in oxysterols and
following a dietary cholesterol challenge. In addition, the levels of oxysterols, including 25HC, have been found to be
elevated in hypercholesterolemic serum.
Methodology/Principal Findings: Here, we demonstrate that the estrogen receptor (ER) a mediates gene expression
changes and growth responses induced by 25HC in breast and ovarian cancer cells. Moreover, 25HC exhibits the ERa-
dependent ability like 17b-estradiol (E2) to inhibit the up-regulation of HIF-1a and connective tissue growth factor by
hypoxic conditions in cardiomyocytes and rat heart preparations and to prevent the hypoxia-induced apoptosis.
Conclusions/Significance: The estrogen action exerted by 25HC may be considered as an additional factor involved in the
progression of breast and ovarian tumors. Moreover, the estrogen-like activity of 25HC elicited in the cardiovascular system
may play a role against hypoxic environments.
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Introduction
The estrogen receptor (ER) a and b belong to the nuclear
receptor superfamily of ligand-inducible transcription factors [1].
The binding of 17b-estradiol (E2) to ERs induces receptor
homodimerization and interaction with specific estrogen respon-
sive elements (EREs) located within the regulatory regions of target
genes [2]. Two separate activation domains mediate the ER-
dependent transcriptional activity: the activation function (AF)-1
located in the amino-terminus and the hormone-dependent AF-2
located in the ligand binding domain (LBD) [3]. The binding of
ligands to ER induces the formation of an AF-2 hydrophobic
pocket which regulates the recruitment of cofactors and impor-
tantly receptor pharmacology [4–5].
Previous results obtained in both cell culture and animal models
have indicated that ERa plays a crucial role in mediating the
effects of estrogen in mammary gland development and breast
cancer progression [6–7]. Moreover, estrogen has been shown to
prevent vascular dysfunction and injury in an ER-dependent
manner [8–10], to reduce cardiomyocyte hypertrophy [11] and to
decrease infarct size and myocyte apoptosis in animal models with
coronary occlusion [12]. Diverse mechanisms are involved in the
protective action exerted by E2 in cardiomyocytes. Oxidative
stress and the subsequent generation of reactive oxygen species
(ROS) are thought to trigger cardiomyocyte apoptosis [13], while
the ability of E2-activated ER to counteract these redox
intermediates is very likely a key factor of overall cardioprotection.
The cell response to lowered oxygen environment implicates the
hypoxia-inducible-factor-1 (HIF-1), which regulates the expression
of genes like the matricellular protein named Connective Tissue
Growth Factor (CTGF) belonging to the CCN family of growth
regulators (cyr61, CTGF and nov) [14]. The levels of CTGF are up-
regulated during wound repair [15], inflammation [16], fibrotic
disorders [17], tumor growth [18–19] and angiogenesis [18,20].
Accumulating evidence has also suggested that CTGF exerts a
crucial role in cardiac fibrotic processes, indicating it as a possible
biomarker and a potential candidate for therapeutic intervention
[21].
Oxysterols are hydroxylated derivatives of cholesterol that play
important functions in lipid metabolism [22]. 25-hydroxycholes-
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hydroxylase [23], acts as a potent inhibitor of cholesterol
biosynthesis in different cell types [24]. 25HC was detected in
rat plasma after ingestion of a meal rich in oxysterols and
following a dietary cholesterol challenge [25]. Likewise, the levels
of oxysterols, including 25HC, were higher in hypercholesterol-
emic serum compared to those found in normocholesterolemic
serum [26]. Next, mice deficient in the oxysterol-catabolizing
enzyme oxysterol 7a-hydroxylase (Cyp7b) showed elevated
concentrations of both 25HC and 27HC, suggesting a regulatory
role elicited by Cyp7b on these hydroxylated cholesterol
derivatives [27].
In the present study, we demonstrate that 25HC elicits
estrogenic effects activating ERa-mediated signaling either in
breast and ovarian cancer cells or in cardiomyocytes. The results




17b-estradiol (E2), 25-hydroxycholesterol (25HC), cobalt chlo-
ride (CoCl2), PD98059 (PD), SB202190 (SB) and actinomycin D
were purchased from Sigma-Aldrich, Inc., Milan, Italy. The
experiments performed using 25HC from Sigma-Aldrich, Inc.,
Milan (Italy) were confirmed with 25HC purchased from Research
Plus, Inc., Barnegat, NJ. ICI 182,780 (ICI) was obtained from
Tocris Chemicals. All compounds were solubilized in dimethyl
sulfoxide (DMSO), except E2 and PD, which were dissolved in
ethanol.
Cell Culture
Breast cancer MCF7 and human embryonal kidney Hek293
cells were maintained in DMEM with phenol red supplemented
with 10% FBS. Breast SkBr3 and ovarian BG-1 cancer cells were
maintained in RPMI1640 and DMEM, respectively, without
phenol red supplemented with 10% FBS. The murine cardiomy-
ocyte-like cell line HL-1 was kindly provided by Dr. William C.
Claycomb (Louisiana State University Medical Center, New
Orleans, LA). HL-1 cells were cultured according to the published
protocol [28] in Claycomb medium (JRH Biosciences, Sigma-
Aldrich, Inc., Milan, Italy) supplemented with 10% FBS (JRH
Bioscience, Sigma-Aldrich, Inc., Milan, Italy), 100mg/ml penicil-
lin/streptomycin, 0.1mM norepinephrine (Sigma-Aldrich, Inc.,
Milan, Italy) and 2mM l-glutamine (Invitrogen, Milan, Italy). All
cell lines were grown in a 37uC incubator with 5% CO2. For
hypoxic stimulation HL-1 cells were treated with CoCl2 or
cultured in presence of low oxygen tension (2% O2) in a HeraCell
incubator (ThermoScientific-Heraeus, Milan, Italy). All cell lines
to be processed for immunoblot and RT-PCR assays were
switched to medium without serum and phenol red 24 h before
treatments.
Transfections, luciferase assays and gene silencing
experiments
Plasmids and Luciferase Assays were previously described
[29–32]. In particular, we used expression vectors encoding the
full length ERa and the ERb form encoding the 485 aa protein
[29–32]. Cells were plated into 10-cm dishes, maintained in
serum-free medium for 24 h and then transfected for additional
24 h before treatments using Fugene6 (Roche Molecular Bio-
chemicals, Milan, Italy) and appropriate control vectors. The
SureSilencing
TM shRNA plasmids for mouse HIF-1a and
respective negative control plasmids (shRNA) were purchased
from Superarray Bioscience Corporation (Frederick, MD, USA)
and were used according to the manufacturer’s recommendations
(Cat. KM03799P). Briefly, cells were plated into 10-cm dishes, and
then transfected in serum-free medium for 24h before treatments
with a mixture containing 15ml/plate Fugene6 Reagent and 5mg/
plate control shRNA or shRNA HIF-1a (shHIF-1a) plasmid. For
HIF-1a silencing, the manufacturer provides 4 separate short
hairpin RNA (shRNA) pre-designed sequences for the same gene,
packaged in 4 separate plasmid backbones (numbered as 1–4). In
our experiments, a single independent shRNA plasmid sequence
(n.3) was sufficient to silence HIF-1a gene expression. The control
shRNA is a scrambled artificial sequence which does not match
any human, mouse or rat gene.
ERa binding assays
The ability of 25HC to compete with [3H]E2 for binding to ERa
was evaluated either in MCF7 cells or using Hek293 cell lysates in
presence or absence of two picomoles of purified recombinant
human ERa protein purchased from PanVera, Invitrogen S.r.l.
Milan, Italy. MCF7 cells were stripped of any estrogen by keeping
them in medium without serum for 2 days, thereafter cells were
incubated with 1nM [2,4,6,7-3H]E2 (89 Ci/mmol; Ge Healthcare,
Milan, Italy) and increasing concentrations of nonlabeled E2 or
25HC for 2 h at 37uC in a humidified atmosphere of 95% air/5%
CO2. After removal of the medium, cells were washed with ice-cold
PBS/0.1% methylcellulose twice, harvested by scraping and
centrifugation, and lysed with 100% ethanol, 500 ml per 60 mm
dish, for 10 min at room temperature [33]. The radioactivity of
extractswasmeasuredbyliquid scintillationcounting.Bindingassay
was also performed using Hek293 whole cell lysates. Cells were
stripped of any estrogen by keeping them in medium without serum
for2 days, and then lysedin500ml of RIPA buffer (20mMTris-HCl,
pH 7.5; 100mM NaCl; 0.5% Nonidet P-40; 0.5mM EDTA) in
presence of a mixture of protease inhibitors containing 1,7 mg/ml
aprotinin, 1 mg/ml leupeptin, 200 mmol/liter phenylmethylsulfo-
nylfluoride, 200 mmol/liter sodiumorthovanadate and 100 mmol/
liter sodium fluoride. Protein concentration was determined using
Bradford reagent according to the manufacturer’s recommenda-
tions (Sigma-Aldrich, Inc., Milan, Italy). Equal amounts of whole-
protein extract were incubated in the absence or presence of two
picomoles of recombinant ERa and incubated with 1nM [3H]E2
and increasing concentrations of unlabeled E2 or 25HC for 2 h at
4uC. Bound and free radioligands were separated on Sephadex G-
25 PD-10 columns. The amount of receptor-bound [3H]E2 was
determined by liquid scintillation counting.
Chromatin immunoprecipitation (ChIP) and Re-ChIP
assays
MCF7 cells were grown in 10-cm dishes to 70–80% confluence,
shifted to serum free medium for 24 h and then treated with
vehicle, 10nM E2 or 1mM 25HC for 1 h. Thereafter, cells were
cross-linked with 1% formaldehyde and sonicated. Supernatants
were immunocleared with sonicated salmon DNA/protein A
agarose (Upstate Biotechnology, Inc., Lake Placid, NY) and
immunoprecipitated with anti-ERa antibody or non specific IgG
(Santa Cruz Biotechnology, DBA, Milan, Italy). Pellets were
washed, eluted with a buffer consisting of 1% SDS and 0.1 mol/L
NaHCO3, and digested with proteinase K. DNA was obtained by
phenol/chloroform extraction and precipitated with ethanol. A
4 ml volume of each sample was used as template to amplify an
ERE-containing region located in the pS2 promoter by real-time
PCR (Applied Biosystems, Milan, Italy). The primers used were
59-GGCCATCTCTCACTATGAATCACTTCTGC-39 (pS2 for-
ward) and 59-GGCAGGCTCTGTTTGCTTAAAGAGCG-39
25-Hydroxycholesterol Activates ERa Signaling
PLoS ONE | www.plosone.org 2 January 2011 | Volume 6 | Issue 1 | e16631Figure 1. 25HC activates ERa. (A) MCF7 cells were transfected with an ER luciferase reporter gene along with the internal transfection control
Renilla Luciferase and treated with increasing concentrations (logarithmic scale) of E2 and 25HC. Moreover, cells were treated simultaneously with
similar doses of each compound. The normalized luciferase activity values of cells treated with vehicle (-) were set as 1-fold induction, upon which the
activity induced by treatments was calculated. (B) MCF7 cells transfected with the ER reporter gene were treated with 10nM E2 or 1mM 25HC alone
and in combination with increasing concentration of the ER antagonist ICI, as indicated. Each data point represents the mean 6 SD of three
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immunoprecipitation. In Re-ChIP experiments, complexes were
eluted by incubation for 30 min in Re-IP buffer (0.5 mM
dithiothreitol, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-Cl
pH 8.1, 150 mM NaCl) and subjected to the ChIP procedure,
using anti-SRC-1, SRC-3 and CBP antibodies (all purchased from
Santa Cruz Biotechnology, DBA, Milan, Italy).
Reverse transcription and real-time PCR
Gene expression was evaluated by real-time PCR as we
previously described [32]. For pS2, PR, Cathepsin D, Cyclin A,
Cyclin D1, HIF-1a, CTGF, FAS, SERPINF1, HSPA1L, SE-
LENBP1 and the ribosomal protein 18S, which was used as a
control gene to obtain normalized values, the primers were: 59-
GCCCCCCGTGAAAGAC-39 (pS2 forward) and 59-CG-
TCGAAACAGCAGCCCTTA-39 (pS2 reverse); 59-GAGTTGT-
GAGAGCACTGGATGCT-39 (PR forward) and 59-CAACTG-
TATGTCTTGACCTGGTGAA-39 (PR reverse); 59-CTGGATC-
CACCACAAGTACAACA-39 (Cathepsin D forward) and 59-
CGAGCCATAGTGGATGTCAAAC-39 (Cathepsin D reverse);
59-TGCACCCCTTAAGGATCTTCCT-39 (Cyclin A forward)
and 59-GTGAACGCAGGCTGTTTACTGT-39 (Cyclin A re-
verse); 59-GTCTGTGCATTTCTGGTTGCA-39 (Cyclin D1 for-
ward) and 59-GCTGGAAACATGCCGGTTA-39 (Cyclin D1
reverse); 59-TGCATCTCCATCTTCTACCCAAGT-39 (HIF-1a
forward) and 59-CCGACTGTGAGTGCCACTGT-39 (HIF-1a
reverse); 59-CATTAAGAAGGGCAAAAAGTGCAT-39 (CTGF
forward) and 59-TGCAGCCAGAAAGCTCAAACT-39 (CTGF
reverse); 59-CGCTCGGCATGGCTATCT-39 (FAS forward) and
59-CTCGTTGAAGAACGCATCCA-39 (FAS reverse); 59-
CCCGGATCGTCTTTGAGAAG-39 (SERPINF1 forward) and
59-TCCAGAGGTGCCACAAAGCT-39 (SERPINF1 reverse); 59-
CCGTGCCAGCCTATTTCAAT -39 (HSPA1L forward) and 59-
AGCAATCACACCTGCATCCTT-39 (HSPA1L reverse); 59-
GCAGCGCCATGAGATTGTG-39 (SELENBP1 forward) and
59-CGGATCTCCAAGGGAATAAGC-39 (SELENBP1 reverse),
and 59-GGCGTCCCCCAACTTCTTA-39 (18S forward) and 59-
GGGCATCACAGACCTGTTATT-39 (18S reverse), respectively.
Immunoblotting
Cell lysates and immunoblotting assays were performed as
previously described [32]. The antibodies against ERa (F-10),
Cyclin D1 (M-20), CTGF (L-20), phosphorylated ERK1/2 (E-4)
and ERK2 (C-14), b-actin (C-2) and b-tubulin (H-235-2) were
purchased from Santa Cruz Biotechnology (DBA, Milan, Italy).
ERb and HIF-1a were purchased from R&D Systems, Inc.
(Milan, Italy). Phospho-p38MAPK (Thr180/Tyr182) and
p38MAPK were purchased from Cell Signalling Technology,
Inc. (Milan, Italy).
Proliferation and TUNEL assays
Quantitative proliferation assays were performed as previously
described [32]. HL-1 cells were plated in 2-well Lab-TekH II
chamber slides and treated for 18 h. After removing medium, cells
were fixed in 4% buffered paraformaldehyde (pH 7.4) for 30 min.
Slides were rinsed twice in PBS, pH 7.4. An in situ cell death
detection kit (DeadEnd
TM, Fluorometric TUNEL System, Pro-
mega Corp, Milan, Italy) was subsequently used to perform DNA
39-hydroxyl end labelling by TUNEL (Terminal deoxynucleotidyl
Transferase (TdT)-mediated dUTP-X Nick End Labelling) assay
as previously described [34]. Labelling of cells was shown to be
correlated with typical morphological criteria of apoptosis. DNA
was labelled in 39-ends with fluorescein-dUTP by incubation at
37uC with reaction buffer containing TdT in a humidified
chamber for 1 h. Nuclei of cells were stained with propidium
iodide. After three washes in PBS, apoptotic DNA fragmentation
was directly detected by visualization of labelled DNA using
fluorescent microscope. For negative control, slides were incubated
without TdT; to obtain positive control, slides were treated with
Figure 2. ERa ligand binding assays. The graphs show residual binding of the radioactive tracer in the presence of increasing concentrations of
unlabelled E2 and 25HC in MCF7 cells (A), in Hek293 cell lysates in the presence (B) or absence of recombinant ERa protein (C). Each data point
represents the mean 6 SD of triplicate samples of three separate experiments. Note that the amount of tracer bound in the absence of competitor
was arbitrarily set to 100% and that the underlying absolute values differ between the three panels.
doi:10.1371/journal.pone.0016631.g002
experiments performed in triplicate. (C–F) Hek293 cells were transfected with ER luciferase reporter gene (EREluc) and ERa (C) or ERb (D) expression
plasmids, with Gal4 reporter gene GK1 and the Gal4 fusion proteins encoding the Ligand Binding Domain (LBD) of ERa (GalERa) (E) or ERb (GalERb) (F)
and treated with 10nM E2 or 1mM 25HC alone and in combination with 10mM ER antagonist ICI, as indicated. Each data point represents the mean 6
SD of three experiments performed in triplicate.
doi:10.1371/journal.pone.0016631.g001
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to fluorescein dUTP and TdT.
Isolated and perfused heart preparations
All experimental protocols were approved by the Committee on
the Use of Animals of the Pharmaco-Biology Department at the
University of Calabria (approval ID 110/2000A). The procedures
followed in the study were in accordance with the European
Community standards on the care and use of laboratory animals
and with the Guide for the Care and Use of Laboratory Animals published
by the US National Institutes of Health (NIH Publication No. 85-
23, revised 1996). Adult male rats (Wistar, 220–280g, Harlan,
Udine, Italy) were anaesthetized by i.p. injection of ethyl
carbamate (2 g/kg body weight). Hearts were then dissected out
and connected to a Langendorff apparatus for perfusion with a
Krebs–Henseleit solution (KHs) composed of (in mM) NaCl 113,
KCl 4.7, NaHCO3 25, MgSO4 1.2, CaCl2 1.8, KH2PO4 1.2,
glucose 11, mannitol 1.1, Na-pyruvate 5 and gassed with 95%O2-
5%CO2 (pH7.4, 37uC). KHs was delivered at a constant flow-rate
of 12 mL/min. To measure cardiac activity, a water-filled latex
balloon, connected to a BLPR gauge (WRI, Inc. USA), was
inserted through the mitral valve into the left ventricle to allow
isovolumic contractions and to continuously record mechanical
parameters. The balloon was progressively filled with water to
obtain an initial left ventricular end diastolic pressure of 5 to
8 mmHg [35]. All hearts were perfused for a 15 min equilibration
period. After the equilibration period, the hearts (n=3) were
randomly assigned to one of the following groups: Group 1
(control): KH gassed with 95%O2-5%CO2; Group 2: KH gassed
with 95%O2-5%CO2 plus 1nM E2; Group 3: KH gassed with
95%O2-5%CO2 plus 100nM 25HC; Group 4: KH gassed with
50%O2-45%N2-5%CO2; Group 5: KH gassed with 50%O2-45%
N2-5%CO2 plus 1nM E2; Group 6: KH gassed with 50%O2-45%
N2-5%CO2 plus 100nM 25HC.
All hearts were perfused for 60 minutes to investigate the effect
of each compound and of the different oxygen levels on the
changes of CTGF and HIF-1a mRNA expression. Solution
containing treatments was freshly prepared before experiments.
Left ventricular pressure, heart rate and coronary flow were
monitored throughout the perfusion protocol. At the end of the
perfusions, ventricles were excised and immediately processed for
RNA extraction.
Statistical Analysis
Statistical analysis was done using ANOVA followed by
Newman-Keuls’ testing to determine differences in means.
P,0.05 was considered as statistically significant.
Results
25HC activates ERa in cancer cells
We began evaluating whether 25HC is able to transactivate a
transiently transfected ER reporter gene in breast cancer cells
(MCF7), which express ERa and not ERb as judged by RT-PCR
(data not shown). Interestingly, 25HC activated ERa in a dose-
dependent manner, although with a lower efficacy compared to
E2 (Fig. 1A). We next evaluated whether 25HC could antagonize
the transcriptional activation induced by E2. MCF7 cells were
then treated simultaneously with increasing concentrations of both
25HC and E2, however the transcriptional responses were similar
to those obtained used E2 alone (Fig. 1A). On the contrary, the
luciferase activity induced by 10nM E2 or 1mM 25HC were
abrogated using increasing doses of the ER antagonist ICI
(Fig. 1B), suggesting that ERa mediates the transcriptional
Figure 3. 25HC up-regulates the expression of estrogen target
genes. (A) E2 and 25HC induce the recruitment of ERa to the ERE site
located in the pS2 promoter sequence in MCF7 cells. Cells were treated
for 1 h with vehicle, E2 (10nM) or 25HC (1mM) and submitted to the
chromatin immunoprecipitation procedure using anti-ERa or nonspe-
cific anti-IgG antibodies. For Re-ChIP assays, anti-SRC-1, SRC-3 and CBP
antibodies were used. The amplified sequences were evaluated by real-
time PCR. (B–C) evaluation of mRNA expression of pS2, Progesterone
Receptor (PR), Cathepsin D, Cyclin A and Cyclin D1 by real-time PCR in
MCF7 and BG-1 cells. Cells were treated for 24h with 10nM E2 and 1mM
25HC. Results obtained from experiments performed in triplicate were
normalized for 18S expression and shown as fold change of RNA
expression compared to cells treated with vehicle. Each data point
represents the mean 6 SD of three experiments performed in triplicate.
(N), (u), (&), (%)( ¤) indicate p,0.05 for cells receiving vehicle (–) versus
treatments.
doi:10.1371/journal.pone.0016631.g003
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data regarding the ability of 25HC to activate ERa and to evaluate
whether ERb could also respond to 25HC, we transiently
transfected ER-negative Hek293 cells with the ER reporter gene
along with the expression vector encoding ERa or ERb. Of note,
only ERa expression allowed 1mM 25HC to induce the luciferase
activity, which was abolished by 10mM ICI (Fig. 1C–D). To
provide further evidence regarding the ability of 25HC to activate
ERa but not ERb, we turned to a completely heterologous system.
In Hek293 cells, 1mM 25HC activated a chimeric protein
consisting of the DNA binding domain (DBD) of the yeast
transcription factor Gal4 and the LBD of ERa but not ERb
(Fig. 1E–F). Again, the transactivation of ERa was abolished by
10mM ICI (Fig. 1E–F). To corroborate the aforementioned
findings, we ascertained whether 25HC could induce the
expression of the ERb target genes SERPINF1, HSPA1L,
SELENBP1, which were reported to respond to E2 treatment
[36]. Using Hek293 cells transiently transfected with an ERb
expression plasmid, the transcription of these genes was stimulated
by E2 but not by 25HC (Fig. S1). Taken together, these results
demonstrate that 25HC activates ERa in a selective manner and
show that ERa-LBD is sufficient for the transcriptional response.
On the basis of the results obtained in transfection experiments,
we asked whether 25HC could behave as a ligand and compete
with E2 for the binding to ERa. In a whole cell binding assay with
MCF7 cells 25HC displaced the radiolabeled E2 in a dose-
dependent manner (Fig. 2A). Similarly, when recombinant ERa
was added to a Hek293 cell lysate, which by itself does not bind
E2, 25HC competed efficiently against the tracer E2 (Fig. 2B–C).
The results of these binding assays are compatible with the idea
that 25HC binds ERa directly, but further experiments will be
necessary to establish the mode of action unambiguously.
25HC induces the recruitment of ERa to the pS2
promoter sequence in MCF7 cells
On the basis of the aforementioned findings, we evaluated
whether 25HC could induce the recruitment of ERa to targeted
ERE-containing DNA region within the pS2 promoter sequence.
Performing a chromatin immunoprecipitation (ChIP) assay in
MCF7 cells, 1h treatment with 1mM 25HC induced the
recruitment of ERa to the pS2 promoter as observed using
10nM E2 (Fig. 3A). Moreover, to verify whether 25HC may
recruit co-activators to the pS2 promoter, we performed Re-ChIP
assay using antibodies against SRC-1 and SRC-3, which belong to
the steroid receptor co-activator (SRC) families and against CBP
(CREB-binding protein) [37]. All co-activators were efficiently
recruited to the pS2 promoter exposing MCF7 cells to 10nM E2,
however 1mM 25HC showed a slight efficacy (Fig. 3A). Hence, E2
and 25HC display a different ability in recruiting co-activators,
which contribute to the agonistic potency of ligands.
25HC regulates the expression of ERa target genes in
MCF7 and BG-1 cells
We next evaluated the potential of 25HC to regulate the
expression of well known ERa target genes, such as pS2, PR,
Cathepsin D, Cyclin A and Cyclin D1 in MCF7 breast and BG-1
ovarian cancer cells. As determined by real-time RT-PCR, a 24 h
exposure to 1mM 25HC up-regulated the mRNA expression of all
genes examined, similar to the treatment with 10nM E2 (Fig. 3B–
C). To further corroborate these findings, we investigated the
ability of 25HC to modulate the expression of ERa and Cyclin D1
protein levels in MCF7 and BG-1 tumor cells. To date, the down-
regulation of ERa by estrogen has been considered a hallmark of
receptor activation [38], while the up-regulation of Cyclin D1 by
E2 has been extensively reported [39]. Notably, a 24 h exposure to
1mM 25HC down-regulated ERa protein levels (Fig. 4A–B). On
the contrary, a 24 h treatment with 1mM 25HC up-regulated
Cyclin D1 protein expression, which was abrogated by 10mM ICI
(Fig. 4C–D). Altogether, these results suggest that 25HC is able to
regulate the expression of ERa target genes like E2.
25HC induces proliferative effects in MCF7 and BG-1 cells
Then, we sought to evaluate the biological counterpart of the
above-mentioned effects exerted by 25HC. Growth assays
performed in MCF7 and BG-1 cancer cells demonstrated that
25HC is able to induce proliferative effects in a dose dependent
manner (Fig. 4E and 4G). Next, the growth responses to 10nM E2
and 1mM 25HC were abolished by 10mM ICI (Fig. 4F and 4H),
suggesting that ERa mediates cell proliferation induced upon
exposure to both compounds.
25HC mimics the effects of E2 against hypoxia-induced
apoptosis in cardiomyocytes
To further evaluate the estrogenic properties of 25HC, we
turned to a completely different model system like the HL-1
cardiomyocytes [28], which express ERa and very low ERb levels
as judged by RT-PCR (data not shown). It has been reported that
E2 protects cells from hypoxic insult in different cell contexts
[40–42]. Hence, we evaluated whether E2 and 25HC could
protect HL-1 cardiomyocytes from apoptosis induced by the well
known hypoxia-mimetic agent CoCl2 [43–44]. Determining DNA
degradation by TUNEL assay, approximately 70% of HL-1 cells
resulted positive for TUNEL staining after exposure to CoCl2
(Fig. 5 and Fig. S2). Of note, the percentage of apoptotic cells was
significantly reduced in presence of either 10nM E2 or 1mM 25HC
(Fig. 5 and Fig. S2). The protective effects exerted by both
compounds were abrogated using 10mM ICI, which alone did not
induce apoptosis (Fig. 5 and Fig. S2). Taken together, the results
shown indicate that E2 and 25HC may protect cardiomyocytes
from hypoxia-induced apoptosis in an ER-dependent manner.
E2 and 25HC prevent the hypoxia-induced expression of
HIF-1a and CTGF in cardiomyocytes
It has been previously reported that HIF-1a mediates CTGF
expression stimulated by hypoxia in different cell contexts [45–47].
Whilst the potential regulation of HIF-1a by E2 has been
suggested in certain models [48–49], the estrogen ability to
influence hypoxia-induced CTGF expression in the cardiovascular
system remains to be investigated. On the basis of these
observations, we ascertained that HIF-1a and CTGF are up-
Figure 4. 25HC induces cancer cell proliferation. Immunoblots of ERa (A, B) and Cyclin D1 (C, D) from MCF7 and BG-1 cells. Cells were treated
for 24h with vehicle (-), 10nM E2 or 1mM 25HC and in presence of 10mM ER-antagonist ICI, as indicated. b-actin serves as loading control. 25HC
induces proliferative effects in MCF7 and BG-1 cells (E–H). Cells were treated for 5 days with increasing concentrations (logarithmic scale) of E2 and
25HC and counted on day 6 (E,G). Cells were treated with 10nM E2 or 1mM 25HC and in combination with 10mM ER-antagonist ICI and counted on day
6 (F,H). Proliferation of cells receiving vehicle was set as 100% upon which cell growth induced by treatments was calculated. Each data point is the
average 6 SD of three independent experiments. (N), (u) indicate p,0.05 for cells receiving vehicle (–) versus treatments.
doi:10.1371/journal.pone.0016631.g004
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PLoS ONE | www.plosone.org 7 January 2011 | Volume 6 | Issue 1 | e16631Figure 5. E2 and 25HC prevent CoCl2-induced apoptosis in HL-1 cells. Apoptotic changes were detected using TUNEL (in green) and nuclei
were stained by propidium iodide (PI, in red), as indicated. Representative photographs after 18h treatment with vehicle and 100mM CoCl2, 10nM E2,
1mM 25HC alone, or a combination of 100mM CoCl2 with 10nM E2 in presence or absence of 10mM ICI, 100mM CoCl2 with 1mM 25HC in presence or
absence of 10mM ICI.
doi:10.1371/journal.pone.0016631.g005
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manner by 100mM CoCl2 in HL-1 cells (Fig. 6A,C). Similar
responses were observed incubating HL-1 cells in presence of low
oxygen tension (2% O2) (Fig. 6B,D). Next, the hypoxia-induced
expression of HIF-1a and CTGF was abolished using the inhibitor
of DNA-primed RNA synthesis actinomycin D (Fig. S3),
suggesting that transcriptional mechanisms are responsible for
the up-regulation of both HIF-1a and CTGF. Then, we
determined that the silencing of HIF-1a abrogates CTGF
induction observed either upon exposure to CoCl2 or hypoxic
conditions (2% O2) (Fig. 6E–F), indicating that HIF-1a mediates
the up-regulation of CTGF by hypoxia in HL-1 cells. Thereafter,
we asked whether E2 and 25HC might influence HIF-1a and
CTGF expression. Interestingly, we found that either 10nM E2 or
1mM 25HC prevent the up-regulation of HIF-1a and CTGF
either by CoCl2 or low oxygen tension (2% O2) at both mRNA
(Fig. S4) and protein levels (Fig. 7A–B). However, this ability of E2
and 25HC was abolished using 10mM ICI (Fig. 7A–B and Fig. S4),
suggesting that the action of both compounds involves an ER-
mediated mechanism. To provide further data regarding the
intracellular signaling regulating HIF-1a and CTGF expression,
we established that 10nM E2 and 1mM 25HC phosphorylate
ERK1/2 and p38MAPK in a rapid manner (Fig. 8A). Accord-
ingly, in presence of the inhibitors of these kinases, PD and SB
respectively, both E2 and 25HC lost the repressive effects exerted
on the up-regulation of HIF-1a and CTGF at both mRNA and
protein levels (Fig. 8B–C and Fig. S4). Altogether, these results
suggest that 25HC triggers both ER and kinase-mediated signaling
similar to E2.
HIF-1a and CTGF mRNA induction by hypoxia is
prevented by E2 and 25HC in perfused rat hearts
On the basis of the aforementioned results, we examined
whether hypoxia could increase HIF-1a and CTGF mRNA
expression in isolated and perfused rat heart preparations.
Following the experimental conditions described in Materials
and Methods section, rat ventricles were excised after 1h exposure
to low pO2 levels (40%) and subjected to RNA extraction and
real-time PCR evaluation. Interestingly, the up-regulation of both
HIF-1a and CTGF expression by hypoxia was abrogated in
presence of 1nM E2 or 100nM 25HC (Fig. 9), confirming the
results obtained in HL-1 cells.
Discussion
25HC has been implicated in a variety of relevant metabolic-
related events, such as cellular cholesterol homeostasis and
atherosclerosis [22]. Moreover, 25HC was shown to be more
potent than cholesterol in stimulating cells to respond to high
sterol levels either decreasing 3-hydroxy-3-methylglutaryl coen-
Figure 6. Evaluation of HIF-1a and CTGF expression in HL-1 cells. HIF-1a and CTGF mRNA expression were evaluated by real-time PCR after
100mM CoCl2 treatment (A) and incubating HL-1 cells under hypoxia (2%O2) (B). Results obtained from experiments performed in triplicate were
normalized for 18S expression and shown as fold change of RNA expression compared to cells treated with vehicle (A) or cultured under normoxia
(B). (C) immunoblots of HIF-1a and CTGF from HL-1 cells after treatment with vehicle (-) or 100mM CoCl2, as indicated. b-tubulin serves as a loading
control. Side panel shows densitometric analysis of the blots, normalized to b-tubulin. (D) immunoblots of HIF-1a and CTGF from HL-1 cells cultured
under normoxia or in presence of low oxygen tension (2% O2), as indicated. b-tubulin serves as a loading control. Side panel shows densitometric
analysis of the blots, normalized to b-tubulin. Cells were transfected with a control shRNA or shHIF-1a and exposed for 8h to 100mM CoCl2 (E) or
hypoxic conditions (2% O2) (F). Side panels show densitometric analysis of the blots, normalized to b-tubulin. (G) efficacy of HIF-1a silencing obtained
using shHIF-1a. Each data point is the average 6 SD of three independent experiments. (N), (u) indicate p,0.05 for cells receiving vehicle (–) versus
treatments or for cells cultured under normoxia versus cells exposed to hypoxia.
doi:10.1371/journal.pone.0016631.g006
Figure 7. Immunoblots of HIF-1a and CTGF from HL-1 cells. (A) cells were treated for 8h with 100mM CoCl2 or (B) exposed to hypoxia (2% O2),
in combination with 10nM E2, 1mM 25HC and 10mM ICI, as indicated. b-tubulin serves as loading control. Data (mean 6 SD) are representative of
three independent experiments. Side panels show densitometric analysis of the blots, normalized to b-tubulin. (N), (u) indicate p,0.05 for cells
receiving vehicle (–) versus treatments or for cells cultured under normoxia versus cells exposed to hypoxia.
doi:10.1371/journal.pone.0016631.g007
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cholesterol esterification, thereby leading to a decreased synthesis
and/or augmented storage of cholesterol [50]. In the cell, 25HC is
synthesized from cholesterol by auto-oxidation or enzymatically by
a non-heme, iron-containing protein [25,51]. Significant levels of
25HC are produced in different cell contexts [25,52–53] and even
in a selective manner with respect to other cholesterol derivatives,
as occurs in astrocytes [54]. Several studies in animals and humans
have shown that oxysterols, including 25HC, are absorbed in the
gut, transported into the circulation within chylomicrons and then
are taken up into tissues depending on diet and metabolism [55].
Moreover, previous investigations reported different 25HC
plasma levels, ranging from ng/ml [56] to mg/ml [57]. In addition,
25HC has been demonstrated to promote the differentiation of
Leydig cells [58], hepatocytes and keratinocytes [59–60] and to
induce fatty acid synthase (FAS) expression [61], as we confirmed
to occur also in a cell context lacking ERs like SkBr3 breast cancer
cells (Fig. S5). Likewise, 25HC stimulated interleukin-8 secretion
in monocytic THP-1 cells activating the ERK/c-fos/AP-1
transduction pathway in a calcium-dependent manner [62] and
exerted dose-dependent effects on cell proliferation [54,63–64].
In this study, we have demonstrated that 25HC is able 1) to
activate ERa, possibly by binding directly as an agonistic ligand, 2)
to up-regulate diverse estrogen target genes, 3) to modulate ERa
and Cyclin D1 protein levels and 4) to stimulate growth effects in
breast and ovarian cancer cells. In addition, we have shown that
25HC in cardiomyocytes elicits an ER-mediated prevention of
hypoxia-dependent apoptosis and inhibition of the up-regulation
of hypoxia-induced expression of HIF-1a and CTGF. Notewor-
thy, 25HC mimicked the action of E2 to prevent hypoxia-induced
HIF-1a and CTGF expression in isolated and perfused rat heart
preparations.
Recently, it has been reported that the 27HC derivative can
interact with and regulate the activity of both ER isoforms,
triggering diverse biological actions either in vitro or in vivo [65].
In particular, 27HC acted as a selective estrogen receptor
Figure 8. 25HC prevents the hypoxia-induced expression of HIF-1a and CTGF through kinase-mediated signalling. (A) immunoblots
of p-ERK1/2 and p-p38 from HL-1 cells treated for 10 min with vehicle (-), 10nM E2 and 1mM 25HC. Total ERK/2 and p38 serve as loading control. (B)
immunoblots of HIF-1a and CTGF from HL-1 cells exposed for 8h to 100mM CoCl2 or hypoxia (2% O2) (C), in combination with 10nM E2, 1mM 25HC
and 10mMP Do r1 0 mM SB, as indicated. b-tubulin serves as loading control. Data (mean 6 SD) are representative of three independent experiments.
Side panels show densitometric analysis of the blots, normalized to b-tubulin. (N), (u) indicate p,0.05 for cells receiving vehicle (–) versus treatments or
for cells cultured under normoxia versus cells exposed to hypoxia.
doi:10.1371/journal.pone.0016631.g008
25-Hydroxycholesterol Activates ERa Signaling
PLoS ONE | www.plosone.org 11 January 2011 | Volume 6 | Issue 1 | e16631modulator (SERM) on the basis of its agonist/antagonist activities
elicited in a cell- and promoter-dependent manner [66–67]. In
breast cancer cells 27HC stimulated both gene transcription and
growth effects, suggesting its potential role in the progression of
breast tumor in obese/hypercholesterolemic women [66]. Inter-
estingly, 27HC inhibited the transcription-dependent and even
transcription-independent estrogen-mediated production of nitric
oxide by vascular cells leading to a decreased vasorelaxation of rat
aorta upon estrogen exposure [67]. Consequently, 27HC was
indicated as a contributing factor to the loss of estrogen protection
in vascular disease. Collectively, in estrogen-dependent tumor cells
27HC and 25HC exhibited similar stimulatory action, however
they displayed distinct ER-mediated functions according to the
cardiovascular model system used.
In breast and ovarian cancer, E2 stimulates proliferative effects
through ERa [68–70]. On the basis of our results, it could be
possible to suppose that 25HC might be involved in the
progression of breast and ovarian tumors. In this regard, it should
be taken into account that 25HC plasma levels increase after
ingestion of a meal rich in oxysterols, as also detected after a
dietary cholesterol challenge [25]. Indeed, increased cholesterol
levels, which are often associated with obesity [71], are also
detected in women with high risk of breast and ovarian cancer
[72–74].
As it concerns the role of HIF-1a in apoptosis, its function
remains somewhat controversial and appears to be cell type and
context specific [75–78], a number of reports have demonstrated
its contribution to programmed cell death during hypoxia [79–80].
Interestingly, it has been shown that hypoxia-induced HIF-1a
activates ERa [81–82], further associating these transduction
pathways to the intricate balance between factors that induce or
counteract apoptosis in hypoxic conditions. To date, a large body
of evidence has suggested that estrogen-activated ERa favorably
influences cardiomyocyte survival both in vivo and in vitro model
systems [8,40,83–85], explaining the gender-dependent protection
against atherosclerosis and cardiovascular disease [86]. Our
findings confirmed that E2 is able to prevent the hypoxia-induced
apoptosis in cardiomyocytes and this ability was also exhibited by
25HC, which mimicked the potential of estrogen to regulate HIF-
1a expression through ERa along with the rapid intracellular
signaling such as ERK and p38 kinases.
Previous studies have demonstrated that HIF-1a is required for
hypoxic induction of CTGF [47], which is involved in fibrotic
processes in several tissues including the heart [21]. CTGF
expression was found strongly up-regulated in atherosclerotic
plaques [87]. Likewise, in vascular smooth muscle cells (VSMCs)
CTGF overexpression induced apoptosis [88] and led to MMP2
activity [89] which would result in plaque destabilization.
Accordingly, CTGF was mainly detected in complicated plaques
where it stimulated mononuclear cell chemotaxis, acting as a pro-
atherogenic factor [90]. An increased expression of CTGF was
reported in infarcted and non-infarcted cardiac tissues [91–92],
indicating CTGF as an attractive therapeutic target to treat
fibrotic diseases and suggesting the use of its plasma levels as a
biomarker for heart failure [21]. Indeed, our data have provided
novel insight regarding the ERa-mediated ability of both E2 and
25HC to abolish the HIF-1a dependent up-regulation of CTGF in
cardiomyocytes. Most importantly, 25HC displayed similar
activity to E2 in preventing the hypoxia-induced expression of
HIF-1a and CTGF in rat heart preparations, further extending to
an in vivo model system its potential effects against hypoxic
environments.
Here, we have demonstrated that 25HC activates the ER-
mediated signaling in estrogen sensitive breast and ovarian cancer
cells as well as in vascular model systems, hence mimicking the
multifaceted estrogen action.
Supporting Information
Figure S1 mRNA expression of ERb target genes. (A)
evaluation of SERPINF1, HSPA1L and SELENBP1 expression by
real-time PCR in Hek293 cells transfected for 24 h with a vector
or an ERb expression plasmid. Data (mean 6 SD) obtained from
three independent experiments were normalized for 18S expres-
sion and shown as fold change of RNA expression upon treatment
respect to cells treated with vehicle. (B) ERb protein expression in
Hek293 cells transfected with a vector or ERb expression plasmid.
b-actin serves as loading control.
(TIF)
Figure S2 E2 and 25HC prevent CoCl2-induced apopto-
sis in HL-1 cells, as assessed by TUNEL staining.
Quantitative representation of data (mean 6 SD) of three
independent experiments. (u) indicates p,0.05 for HL-1 cells
receiving vehicle (–) versus treatments, as indicated.
(TIF)
Figure S3 Evaluation of HIF-1a and CTGF expression at
both mRNA (A) and protein levels (B). HL-1 cells were
treated with 100nM actinomycin D (Act D) and exposed to
hypoxia (2% O2) for 4h. (A) results obtained from experiments
performed in triplicate were normalized for 18S expression and
shown as fold change of RNA expression of cells exposed to
hypoxia compared to cells cultured under normoxia. (B)
immunoblots of HIF-1a and CTGF from HL-1 cells cultured
under normoxia or hypoxia (2% O2), as indicated. b-tubulin serves
as a loading control. (N), (u) indicate p,0.05 for cells cultured under
normoxia versus cells exposed to hypoxia.
(TIF)
Figure S4 25HC prevents the hypoxia-induced mRNA
expression of HIF-1a and CTGF through ER and kinase-
mediated signalling. HIF-1a and CTGF mRNA expression
evaluated by real-time PCR in HL-1 cells cultured under
Figure 9. Evaluation of HIF-1a and CTGF mRNA expression in
hypoxic rat heart preparations. HIF-1a and CTGF mRNA expression
was evaluated by real time PCR after 1h exposure to low pO2 levels
(40%) and in presence of 1nM E2 or 100nM 25HC treatment, as
indicated. mRNA values obtained from control and hypoxic rat hearts
were normalized for 18S expression and shown as fold change in
triplicate experiments. (u), (N) indicate p,0.05 for control versus hypoxic
rat hearts.
doi:10.1371/journal.pone.0016631.g009
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1mM 25HC in combination with 10mM ICI, 10mMP Do r1 0 mM
SB, as indicated. Results obtained from experiments performed in
triplicate were normalized for 18S expression and shown as fold
change of RNA expression of cells exposed to hypoxia compared
to cells cultured under normoxia. (N), (u) indicate p,0.05 for cells
cultured under normoxia versus cells exposed to hypoxia.
(TIF)
Figure S5 25HC (1mM) induces FAS mRNA expression in
SkBr3 cells, as evaluated by real time PCR. Data (mean
± SD) obtained from three independent experiments
were normalized for 18S expression and shown as fold
change of RNA expression upon treatment respect to
cells treated with vehicle.
(TIF)
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